Pneumology and Thoracic Surgery Service, Unit for Patients with Highly Complex COPD, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
University Institute of Tropical Disease and Public Health of the Canary Islands, University of La Laguna, Santa Cruz de Tenerife, Spain.
Int J Chron Obstruct Pulmon Dis. 2023 Nov 7;18:2473-2481. doi: 10.2147/COPD.S428316. eCollection 2023.
Chronic obstructive pulmonary disease (COPD) has been associated with worse clinical evolution/survival during a hospitalization for SARS-CoV2 (COVID-19). The objective of this study was to learn the situation of these patients at discharge as well as the risk of re-admission/mortality in the following 12 months.
We carried out a subanalysis of the RECOVID registry. A multicenter, observational study that retrospectively collected data on severe acute COVID-19 episodes and follow-up visits for up to a year in survivors. The data collection protocol includes general demographic data, smoking, comorbidities, pharmacological treatment, infection severity, complications during hospitalization and required treatment. At discharge, resting oxygen saturation (SpO2), dyspnea according to the mMRC (modified Medical Research Council) scale and long-term oxygen therapy prescription were recorded. The follow-up database included the clinical management visits at 6 and 12 months, where re-admission and mortality were recorded.
A total of 2047 patients were included (5.6% had a COPD diagnosis). At discharge, patients with COPD had greater dyspnea and a greater need for prescription home oxygen. After adjusting for age, sex and Charlson comorbidity index, patients with COPD had a greater risk of hospital re-admission due to respiratory causes (HR 2.57 [1.35-4.89], p = 0.004), with no significant differences in survival.
Patients with COPD who overcome a serious SARS-CoV2 infection show a worse clinical situation at discharge and a greater risk of re-admission for respiratory causes.
慢性阻塞性肺疾病（COPD）与 SARS-CoV2（COVID-19）住院期间的临床转归/生存率较差有关。本研究的目的是了解这些患者出院时的情况以及在接下来的 12 个月内再次入院/死亡的风险。
我们对 RECovid 登记处进行了亚分析。这是一项多中心、观察性研究，回顾性收集了严重急性 COVID-19 发作和幸存者长达一年的随访数据。数据收集方案包括一般人口统计学数据、吸烟、合并症、药物治疗、感染严重程度、住院期间的并发症和所需治疗。出院时，记录静息血氧饱和度（SpO2）、mMRC（改良医学研究委员会）呼吸困难量表评分和长期氧疗处方。随访数据库包括 6 个月和 12 个月的临床管理就诊，记录再次入院和死亡率。
共纳入 2047 例患者（5.6%诊断为 COPD）。出院时，COPD 患者呼吸困难更严重，需要家庭氧疗的处方更多。在校正年龄、性别和 Charlson 合并症指数后，COPD 患者因呼吸原因再次住院的风险更高（HR 2.57 [1.35-4.89]，p = 0.004），但生存无显著差异。
克服严重 SARS-CoV2 感染的 COPD 患者在出院时的临床情况更差，因呼吸原因再次入院的风险更高。
